Top Tech Companies (1,918)
Don't see your company?
Create a company profile
Bioquark’s core program focuses on developing a novel class of substances termed combinatorial biologics,
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/
InteGen develops innovative FISH probes that are clinically useful and cost-effective tools for the cytogenetics community.
WuXi Advanced Therapies - Accelerating Progress and Time to Market • Integrated Manufacturing and Testing Service Platform • Solutions From Gene of Interest to Global Commercial Launch The advanced therapies business unit of WuXi AppTec is a leading cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Testing, Development and Manufacturing Organization (CTDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing.
RiboMed Biotechnologies is a molecular diagnostic company.
Pulmotect develops products that boost the innate immune system to protect against a wide range of lung infections.
GeneCopoeia, Inc. is a leading provider and manufacture of genomics and proteomics products and services worldwide. GeneCopoeia has developed a series of cutting edge research tools, including the largest collection of expression-ready clones (ORF cDNA, Promoter, shRNA, miRNA), comprehensive genome-editing tools (CRISPR and TALEN), as well as highly efficient viral delivery systems (Lentivirus and AAV). In addition to its genomics and proteomics products, GeneCopoeia also offers fluorescent detection reagents (e.g. non-toxic DNA gel stains, protein gel stains, cell biology assay kits, labeling dyes and antibodies), as well as other molecular biology reagents and kits (e.g. luciferase assay kits, qPCR arrays and products, transfection reagents and more).
Summit Biosciences is developing, manufacturing & commercializing generic and innovative nasal spray drug products.
A nationwide consortium of biomedical professionals and institutions collaborating to provide enhanced networking and mentorship experiences in support of the training and career development of individuals from under represented backgrounds who are pursuing biomedical, behavioral, clinical, and social science research careers (collectively termed biomedical research careers). The NRMN is intended to enable mentees across career stages to find effective mentors who will engage in productive, supportive and culturally responsive mentoring relationships.
Primal Therapies is a biotechnology company that specializes in the fields of biofilm management and healthcare.
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
Blink Science is a biotechnology company that makes handheld, low-cost point-of-care diagnostic testing available across the globe.
Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs, the vast majority of which must be injected. We have developed the RaniPill™ technology to replace subcutaneous or IV injections of biologics with an oral pill. The RaniPill™ capsule is designed to deliver an injection to the intestinal wall, where there are no sharp pain receptors, and has achieved bioavailability similar to subcutaneous injections. We believe oral versions of biologics will have the potential to transform medicine and improve outcomes for the millions of patients who currently rely on chronic self-injections.
Dauntless Pharmaceuticals is a biotechnology company that focuses on the development of drugs.
BrainCo’s leadership draws on deep experience in neuroscience research and expertise in education to deliver entirely new applications of brainwave technology in the education, wellness, and research spaces. We’ve learned important lessons as we’ve grown from a small team in an apartment basement to over 100 employees in 4 offices around the world. Since 2015 we’ve been working on providing the best experience possible for our customers and we’re here to share our progress and innovations with you.
Abilita Bio Inc. is a biotechnology company.
Sciome LLC is an innovative research and technology consulting company providing state of the art informatics solutions for the life sciences industry. We specialize in developing and deploying novel bioinformatics, cheminformatics, text-mining and data science solutions for researchers in government, academic and private sector organizations.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Tavros Therapeutics is a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities. The result is a drug discovery engine that can discover novel drug targets with a clear path forward to the clinic to get the right drugs to the right patients, faster.
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts
